Samia Lopa

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Carmen J. Allegra, Greg Yothers, Michael J. O’Connell et al. · Journal of Clinical Oncology · 2010 · 593 citations

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Carmen J. Allegra, Greg Yothers, Michael J. O’Connell et al. · Journal of Clinical Oncology · 2009 · 258 citations · Full text

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

Carmen J. Allegra, Greg Yothers, Michael J. O’Connell et al. · Journal of Clinical Oncology · 2012 · 208 citations · Full text

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

Mark S. Roh, Greg Yothers, M J O'Connell et al. · Journal of Clinical Oncology · 2011 · 194 citations

Surgical Oncology, Preoperative Multimodality Treatment, Oral Capecitabine +17

Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10

Laurence E. McCahill, Greg Yothers, Saima Sharif et al. · Journal of Clinical Oncology · 2012 · 163 citations · Full text